Nwam LLC Grows Position in GRAIL, Inc. $GRAL

Nwam LLC lifted its position in GRAIL, Inc. (NASDAQ:GRAL) by 93.0% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 20,613 shares of the company’s stock after purchasing an additional 9,932 shares during the period. Nwam LLC owned about 0.06% of GRAIL worth $1,060,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC boosted its position in GRAIL by 21.4% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 34,195 shares of the company’s stock valued at $1,758,000 after buying an additional 6,032 shares during the period. Scientech Research LLC purchased a new position in shares of GRAIL in the first quarter valued at about $644,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in shares of GRAIL during the second quarter valued at about $233,000. Wesbanco Bank Inc. boosted its holdings in shares of GRAIL by 39.1% during the second quarter. Wesbanco Bank Inc. now owns 44,500 shares of the company’s stock worth $2,288,000 after purchasing an additional 12,500 shares during the period. Finally, Dakota Wealth Management purchased a new stake in shares of GRAIL during the second quarter worth about $2,656,000.

Analyst Ratings Changes

A number of brokerages recently issued reports on GRAL. Canaccord Genuity Group boosted their price target on GRAIL from $75.00 to $85.00 and gave the company a “buy” rating in a report on Wednesday, October 22nd. UBS Group set a $75.00 price objective on GRAIL in a research report on Friday, October 3rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of GRAIL in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $60.00.

GRAIL Price Performance

GRAL stock opened at $83.39 on Wednesday. GRAIL, Inc. has a 1 year low of $13.58 and a 1 year high of $103.00. The firm has a 50-day moving average of $63.98 and a 200 day moving average of $47.40. The company has a market cap of $3.01 billion, a P/E ratio of -6.36 and a beta of 4.31.

GRAIL (NASDAQ:GRAL) last posted its earnings results on Tuesday, August 12th. The company reported ($3.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.14) by ($0.04). GRAIL had a negative return on equity of 16.64% and a negative net margin of 329.86%.The firm had revenue of $35.54 million for the quarter, compared to analysts’ expectations of $37.57 million. On average, equities research analysts expect that GRAIL, Inc. will post -15.15 earnings per share for the current fiscal year.

Insider Activity at GRAIL

In related news, CEO Robert P. Ragusa sold 7,239 shares of GRAIL stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $68.88, for a total transaction of $498,622.32. Following the sale, the chief executive officer directly owned 727,388 shares in the company, valued at $50,102,485.44. The trade was a 0.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, President Joshua J. Ofman sold 6,114 shares of the company’s stock in a transaction on Thursday, October 16th. The stock was sold at an average price of $82.01, for a total value of $501,409.14. Following the completion of the sale, the president directly owned 381,818 shares in the company, valued at approximately $31,312,894.18. The trade was a 1.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 117,497 shares of company stock worth $7,515,436 over the last 90 days.

About GRAIL

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.